Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
03/08/2014 you said "I don't see a single thing that leads to monetization of any serious level anytime soon"
And on 08/07/2014 BioHeart responds
Sunrise, Fla – August 7, 2014 – Bioheart, Inc. (BHRT.OB) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart product revenues are up from $24,321 to $819,606 comparing YTD 2013 to YTD 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. Bioheart’s YTD net income increased to $226,034, as compared to a net loss of $1,269,231 in YTD 2013, primarily resulting from gain on settlement of debt.
“The financial backbone of Bioheart is getting stronger and we continue to make strides on a daily basis,” said Mike Tomas, Bioheart's president and CEO. “We have experienced two very strong quarters this year and will try to continue to improve
the well-being of Bioheart for our shareholders.”
Bioheart has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in YTD 2013 down to $507,000 in YTD 2014. Bioheart has been focused on reducing debt and decreasing current liabilities by $3.6 million (27%) from the beginning of the year. In addition, Bioheart has made strides to improve its working capital deficiency, decreasing the deficit by 28% from the beginning of the year.
I suspect the same. IMO I've said it before and I'll say again, we've got an excellent business plan unfolding perfectly. IMO.
Revenue this quarter will hopefully approach 1mil
They gotta get paid. IMO
Exciting news for sure. This screams REVENUE at me!!
Yeah that's crazy, but if proven safe... It could be huge for the field.
Thanks for this!!
"He will meet with the US Food and Drug Administration later this month, and hopes to get approval to start the trial this year." About R. Lanza.
It's only a matter of time now. We know what's coming IMO patience is key.
Haha! Blah blah blah the "blah blah blah"! Stock is still up around 150% YTD.
I didn't notice that, that's awesome. I did notice that only after a couple of hours trading we surpassed the average volume.
My opinion is aligned with yours.
Looks like phase 1 Adipocell results coming soon or better!! IMO
CEO?? Of what??
I understand and agree with your perspective. I found it entertaining cause I have the comfort of already knowing what this company is worth. I agree with the entire outsider perspective of someone trying to do some dd and running into this.
His argument is compelling. He's accurate in his prediction of the NEJM tripling at least IMO.
This guy is drunk... Lol literally.
Thanks chuck!
Where was this disclosed chuck??
This is correct.
Explanation of new name by Robert Lanza
http://www.ipscell.com/2014/09/advanced-cell-technology-reinventing-itself-including-new-name-ocata-therapeutics/
Are you saying NEJM release will be nov 3rd?
The market definitely knows were out here and in a very strategic position IMO.
Awesome. This is why I do not panic... The bigger picture.
My thoughts on the name change...
As we move from being a research and development company to a pharmaceutical company we need appropriate branding.
Also... They must feel that a name change is the final step toward eliminating the "legacy" issues.
The coverage begins.
http://quotes.wsj.com/ACTCD
Nothing at all fuller... It's old news.
Only thing we've been told is that they will all occur before 2015.
It is funny to me to watch everyone turn on each other as the stock sells down instead of up... Everyone calm down. So the SEC released a poorly timed report on a situation we already knew had been settled. This is merely the SECs official report of settlement IMO. ACTCD enlightened us of the settlement as the agreement was reached... I see it as making inside information public, that's all. So now, today the SEC publishes it's conclusion... Big deal. We are still in the same place we were yesterday. This year is going to finish incredibly strong for ACTCD
1. Nasdaq up list
2. NEJM
3. Phase 1 completion
4. Phase 2 outline and start
5. Financing
We have been told a few times by our new leadership that all of this would be completed by years end. DO NOT LIQUIDATE YOUR SHARES and watch the PPS bounce back IMO.
Is it almost show time?
Yup, no need for worry IMO.
Bills gotta get paid IMO. It's nothing to worry about because of things were going to go sour... This would be looked at as trading with insider information.
Last call.
Yes sir!! Strap on your seat belts!!
NEJM release would definitely be welcomed this week. New investors always welcome. I strongly believe that the NEJM TLD is going to set off a chain reaction that will reach the four corners of the world. I'm talking articles, PRs, interviews etc the world will finally see what R. Lanza and ACTCD have been doing and are capable of. Can't wait. IMO
Nasdaq definitely makes sense. I know Both are a waiting game and are both already set in motion IMO. We will just have to wait and see. Although I don't believe we will have to wait too long if this price increase tells a story IMO.
Accurate as always chuck. What do you believe will come first, Nasdaq or TLD??